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Abstract
Glycosaminoglycans (GAGs) are known to play pivotal roles in physiological processes and pathological conditions. To study
interactions of GAGs with proteins, immobilization of GAGs is often required. Current methodologies for immobilization
involve modification of GAGs and/or surfaces, which can be time-consuming and may involve specialized equipment. Here,
we use an efficient and low-cost method to immobilize GAGswithout any (chemical) modification using highly concentrated salt
solutions. A number of salts from the Hofmeister series were probed for their capacity to immobilize heparin and chondroitin-6-
sulfate on microtiter plates applying single chain antibodies against GAGs for detection (ELISA). From all salts tested, the
cosmotropic salt ammonium sulfate was most efficient, especially at high concentrations (80–100% (v/v) saturation).
Immobilized GAGs were bioavailable as judged by their binding of FGF2 and VEGF, and by their susceptibility towards
GAG lyases (heparinase I, II and III, chondroitinase ABC). Using 80% (v/v) saturated ammonium sulfate, block and continuous
gradients of heparin were established and a gradient of FGF2 was created using a heparin block gradient as a template. In
conclusion, high concentrations of ammonium sulfate are effective for immobilization of GAGs and for the establishment of
gradients of both GAGs and GAG-binding molecules, which enables the study to the biological roles of GAGs.
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Introduction
Glycosaminoglycans (GAGs) are an important class of bio-
molecules, consisting of repeating disaccharide units. The
highly negatively charged GAGs are ubiquitously present on
cell surfaces and within the extracellular matrix (ECM), where
they interact with a variety of structural and signaling proteins,
including collagens, growth factors and chemokines [1].
Through these interactions they play a pivotal role in various
physiological processes, like ECM remodeling [2], immune
responses [3] and blood clotting [4]. In addition, GAGs are
also associated with a number of pathological conditions, e.g.
Alzheimer’s disease [5], cancer [6] and chronic obstructive
pulmonary disease [7]. Furthermore, GAGs are used as sup-
plements and coatings in (bio)materials to gain specific bio-
logical properties improving biocompatibility and supporting
tissue repair [2, 8, 9].
The mechanisms underlying the biological roles of GAGs,
including their interactions with biomolecules and cells, large-
ly remain to be elucidated. To be able to study these interac-
tions, GAGs need to be immobilized on surfaces, for example
on a microtiter plate to perform an enzyme-linked
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immunosorbent assay (ELISA). Due to their negative charges
GAGs poorly bind to apolar surfaces like polystyrene micro-
titer plates. A variety of GAG immobilization methods have
been developed by modifying GAGs themselves [10–14],
and/or bymodifying the surface to which the GAGs are bound
[15–18]. GAGs are generally covalently bound by modifica-
tion of the reducing end of the polysaccharide [11, 13–16, 19]
or via the carboxylic groups [10, 12, 14, 18]. Methods to
immobilize GAGs non-covalently include the use of microti-
ter plates coated with allyl amine applying cold plasma poly-
merization techniques requiring a high-cost setup or commer-
cially available allyl amine coated plates [17].
We previously reported on the use of high salt solutions for
linking negatively charged macrobiomolecules, including gly-
cosaminoglycans, to various surfaces (patents US 6,180,769
B1 and US 6,933,379 B2) [20, 21]. This method does not
require additional modification of the GAG nor the surface,
as the GAG can be immobilized directly due to the presence of
the salt. We here extend the use of the salt-based immobiliza-




Ammonium sulfate ((NH4)2SO4), ammonium chloride
(NH4Cl), sodium sulfate (Na2SO4), magnesium sulfate
(MgSO4), sodium chloride (NaCl), lithium chloride (LiCl),
magnesium chloride (MgCl2), magnesium sulfate (MgSO4),
magnesium acetate (Mg(Ac)2), potassium chloride (KCl),
guanidinium chloride (GuHCl), calcium acetate (CaAc) and
bovine serum fraction V (BSA) were purchased from Merck
(Darmstadt, Germany). Calcium sulfate (CaSO4), calcium
chloride (CaCl2), Tween-20® and diethanolamine were pro-
vided by Sigma-Aldrich (St. Louis,MO, USA). p-Nitrophenyl
phosphate disodium salt was obtained from MP Biomedicals
(Santa Ana, CA, USA). UltraPure® Tris was received from
Invitrogen™ (Thermo Fisher Scientific, Waltham, MA,
USA). Heparin sodium was from Organon (Oss, the
Netherlands), heparan sulfate (HS) sodium salt from bovine
kidney and chondroitin-6-sulfate (CSC) sodium salt from
shark cartilage from Sigma-Aldrich and dermatan sulfate
(DS) sodium salt from Celsus laboratories, Inc. (Cincinnati,
OH, USA). Heparinase I, II and II were provided by IBEX
Technologies , Inc. (Montreal , QC, Canada) and
chondroitinase ABC by Sigma-Aldrich. Recombinant human
VEGF 165 protein was from R&D systems (Minneapolis,
MN, USA). Recombinant rat FGF2 was produced in
Escherichia coli using a FGF2 expression construct cloned
in the prokaryotic vector pQE16, which was a gift from the
Department of Pathology, Radboud university medical center,
Nijmegen, The Netherlands [22]. The single chain variable
fragment (scFv) antibodies HS4C3V, IO3H10 and GD3A12
specific for heparin/HS, CS and DS, respectively, were pro-
duced as described and contain a VSV tag [23, 24]. The spec-
ificity of the scFv antibodies were assessed previously by
biochemical/histochemical methods, including ELISA’s and
immunohistochemistry [23, 25, 26]. To detect the scFv anti-
bodies, anti-VSV tag IgG from the mouse hybridoma cell line
P5D4 from the American Type Culture Collection (Rockville,
MD, USA) or polyclonal rabbit anti-VSV-G antibody from
Rockland Immunochemicals Inc. (Limerick, PA, USA) were
used. Rabbit anti-fibroblast growth factor-basic (1–24) anti-
body (immunogen is a synthetic peptide sequence correspond-
ing to bovine FGF2 (1–24)), rabbit anti-goat IgG-alkaline
phosphatase (AP) conjugated and goat anti-rabbit IgG-AP
were obtained from Sigma-Aldrich. Polyclonal goat anti-
humanVEGF 165 antibodywas fromR&D systems and poly-
clonal goat anti-mouse IgG-AP conjugated from Dako,
Agilent Pathology Solutions (Santa Clara, CA, USA). Goat
anti-mouse IgG conjugated with IRDye 800CWand goat anti-
rabbit IgG conjugated with IRDye 680CW were provided by
LI-COR Biotechnology ((Westburg b.v.), Leusden, the
Netherlands). For all ELISA assays, clear flat bottom 96-
wells Microlon® ELISA plates (Item No.: 655092) from
Greiner Bio-One B.V. (Alphen aan de Rijn, the Netherlands)
were used.
Optimization of saturated salt solution for GAG
immobilization
The optimal saturated salt solution to coat GAG to 96-wells
microtiter plates was determined using an indirect ELISA.
First, microtiter plates were incubated with various amounts
of heparin or CSC (500–0 ng/well) dissolved in 80% (v/v)
saturated solutions of various salts i.e. (NH4)2SO4, NH4Cl,
Na2SO4, MgSO4, NaCl, LiCl, MgCl2, MgSO4, KCl, GuHCl,
CaSO4, CaCl2 and MilliQ water. Incubation was overnight on
a wet cloth to minimize fringe effects. The plates were rinsed
six times with PBS containing 0.1% (v/v) Tween-20®
(PBST). After blocking with 1% (w/v) BSA in PBST for
60 min, the scFv antibodies HS4C3V and IO3H10 in 1%
(w/v) BSA in PBST were allowed to bind to the coated hep-
arin and CSC respectively for 60min. Subsequently, the plates
were incubated with mouse anti-VSV antibody P5D4 in 1%
Fig. 1 The immobilization of (a) heparin and (b) chondroitin-6-sulfate
(CSC) on 96-wells microtiter plates using various 80% (v/v) saturated salt
solutions. Immobilized heparin and CSC (incubated at 0–500 ng/well)
were detected via an indirect ELISA using the scFv antibodies HS4C3V
and IO3H10, respectively. Data were normalized against the absorbance
value at 405 nm observed for 500 ng GAGs in 80% (v/v) saturated
(NH4)2SO4 solution, which was added to each plate as an internal refer-
ence. Data are presented as mean with standard error of the mean (n = 3 in
duplicate). MQ=MilliQ water
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(w/v) BSA in PBSTand anti-mouse IgG-AP in 1% (w/v) BSA
in PBST for 60 min. The bound AP conjugated antibody was
detected by addition of 100 μl to each well of 1 mg p-nitro-
phenyl phosphate/ml in 1 M diethanolamine with 0.5 mM
MgCl2, pH 9.8. The conversion of p-nitrophenyl phosphate
into of p-nitrophenol by AP produces a yellow color, which
was measured at 405 nm.
The optimal degree of salt saturation (v/v) to immobilize
heparin, CSC and HS was determined for (NH4)2SO4 using
the samemethod as described above and compared to NaCl as
a less effective salt. The assessed degrees of saturation used
were 100% (v/v), 90% (v/v), 80% (v/v), 70% (v/v), 60% (v/v),
50% (v/v) and 25% (v/v).
Each condition was performed in duplicate and the exper-
iment was repeated three times (n = 3) for heparin and CSC
and four times (n = 4) for HS. Data were normalized against
the absorbance value at 405 nm observed for 500 ng GAGs in
80% (v/v) saturated (NH4)2SO4 solution, which was added to
each plate as an internal reference.
Enzymatic digestion of immobilized GAGs
A 96-wells microtiter plate was incubated with 1 μg/well of
heparin, HS, CSC or DS in 80% (v/v) saturated (NH4)2SO4
solution overnight. The plates were rinsed six times with
PBST after each incubation. After blocking the plate with
1% (w/v) BSA in PBST for 90 min, the GAG-coated wells
were either incubated with a combination of heparinase I, II
and III (0.02 IU of each enzyme in 1 ml 100 mM NaAc with
0.2 mM CaCl2 pH 7.2), with chondroitinase ABC (0.02 IU in
1 ml 25 mM Tris and 2 mMMg(Ac)2 pH 8), or with digestion
buffer only, overnight at 37 °C. Subsequently, the remaining
GAGs were detected with the scFv antibodies HS4C3V,
IO3H10 and GD3A12 using the indirect ELISA method de-
scribed above. Each condition was performed in duplicate and
the experiment was repeated three times (n = 3).
Growth factor binding of immobilized GAGs
Microtiter plates were incubated with 500 ng/well of heparin,
HS, CSC or DS in 80% (v/v) saturated (NH4)2SO4 overnight.
The plates were rinsed six times with PBST after each incu-
bation. After blocking with 1% (w/v) BSA in PBST for
60 min, the GAG-coated microtiter plates coated were incu-
bated with 25 ng/well of either rat FGF2 or human VEGF in
1% (w/v) BSA in PBST for 60 min. The bound growth factors
were detected with rabbit anti-fibroblast growth factor-basic
(1–24) and goat anti-human VEGF 165 antibody and subse-
quently rabbit anti-goat and goat anti-rabbit IgG-AP using the
indirect ELISA method described above. Each condition was
performed in duplicate and the experiment was repeated three
times (n = 3).
Creating a gradient of immobilized heparin and FGF2
A block gradient of heparin was created in a 24-wells Greiner
CELLSTAR® cell suspension plate by diluting 2 μg of hep-
arin in 100 μl of 80% (v/v) saturated (NH4)2SO4 each hour
with an additional 100 μl of 80% (v/v) saturated (NH4)2SO4.
To create a FGF2 gradient, a heparin block gradient was incu-
bated with 400 μl of 200 ng/ml FGF2 in 0.4% (w/v) BSA in
PBS for 60 min. The plate was rinsed six times with PBST,
blocked with 1% (w/v) BSA in PBST for 60 min and incubat-
ed with anti-fibroblast growth factor-basic (1–24) antibody
and goat anti rabbit IgG conjugated IRDye 800CW, 60 min
each, and rinsing with PBSTafter each incubation. To create a
continuous gradient of heparin, 2 μg of heparin in 100 μl of
80% (v/v) saturated (NH4)2SO4 was placed at one side of a
well of a 24-wells cell suspension plate. The heparin was
immediately diluted with 80% (v/v) saturated (NH4)2SO4 so-
lution at a rate of 0.1 ml/h using a pump system (New era
pump systems inc, model number NE-300). After the whole
surface of the well was covered with (NH4)2SO4, the plates
were washed six times with PBSTand blocked with 1% (w/v)
BSA in PBST 60 min. The gradient of heparin was visualized
by successive incubations with HS4C3V, P5D4 and goat anti
mouse IgG conjugated with IRDye 800CW in 1% (w/v) BSA
in PBST for 60 min each and rinsing with PBST after each
incubation. The IRDye staining was visualized using the
Odyssey CLx imaging system, which was further processed
and analyzed with Fiji 1.51n software.
Creating patterns of immobilized heparin and CSC
A clover-shaped mold was designed with Autodesk®
Tinkercad® and 3D printed with polylactic acid using an
adapted Anet® A8 3D printer (Shenzhen Anet Technology
Co., Ltd., Shenzhen, Guangdong, China) (Fig. 6c). The
mold was placed at the bottom of a 24-wells Greiner
CELLSTAR® cell suspension plate (Fig. 6d). A 400 μl
solution of 20 μg/ml of heparin in 80% (v/v) saturated
(NH4)2SO4 was placed inside the mold and incubated over-
night. After removing the mold and rinsing six times with
PBST, the plate was blocked with 1% BSA in PBST. The
pattern of immobilized heparin was visualized using the
antibodies HS4C3V, P5D4 and goat anti mouse IgG conju-
gated with IRDye 800CW in 1% (w/v) BSA in PBST. The
reverse pattern was created by performing the same exper-
iment with CSC placed on the outside of the mold in a
new well of the 24-wells plate. The reverse clover pattern
of CSC was detected with IO3H10, polyclonal rabbit anti-
VSV-G antibody and goat anti rabbit IgG conjugated with
IRDye 680CW in 1% (w/v) BSA in PBST. The IRDye
staining was visualized using the Odyssey CLx imaging
system, which was further processed and analyzed with
Fiji 1.51n.
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Fig. 2 The immobilization of (a)
heparin, (b) chondroitin-6-sulfate
(CSC) and (c) heparan sulfate
(HS) on 96-wells microtiter plates
using various saturation percent-
ages (v/v) of (NH4)2SO4 and
NaCl solutions. Immobilized gly-
cosaminoglycans (GAGs) were
detected via an indirect ELISA
using the scFV antibodies
HS4C3V for heparin and HS and
IO3H10 for CSC. Data were nor-
malized against the absorbance
value at 405 nm observed for
500 ng GAGs in 80% (v/v) satu-
rated (NH4)2SO4 solution, which
was added to each plate as an in-
ternal reference. Data are pre-
sented as mean with standard er-
ror of the mean (heparin, CSC
n = 3 in duplicate; HS n = 4 in
duplicate). MQ=MilliQ water
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Results
Immobilization of GAGs
Heparin and chondroitin-6-sulfate (CSC) were immobilized on
polystyrene plates using 80% (v/v) saturated solutions of various
salts applying 0–500 ng GAG/well, and immobilization was
assessed by an indirect ELISA assay using single chain antibod-
ies against heparin and CSC (See Materials and methods). In
comparison with other salts of the Hofmeister series ammonium
sulfate ((NH4)2SO4) was superior in immobilizing heparin and
CSC (Fig. 1a, b). The amount of GAGs immobilized by
(NH4)2SO4 was dose-dependent. Increasing the concentration
of heparin in the coating solution resulted in a near linear increase
of immobilized heparin, whereas for CSC an initial steep increase
was observed followed by a more gradual increase towards a
maximumvalue. Use of other (cosmotropic) salts resulted in only
minor amounts of GAGs immobilized at the given GAG con-
centration range. Only at the highest amount of CSC (500 ng/
well), 80% (v/v) saturated magnesium sulfate (MgSO4) gave a
positive signal.
Fig. 3 Bioavailability of immobilized glycosaminoglycans. Immobilized
heparin and heparan sulfate (HS) (both incubated at 1 μg/well) were
digested with heparinase I, II and III. Immobilized chondroitin-6-sulfate
(CSC) and dermatan sulfate (DS) were digested with chondroitinase
ABC. The undigested and digested GAGs were detected via an indirect
ELISA using the scFv antibodies HS4C3V for heparin and HS, IO3H10
for CSC and GD3A12 for DS. Data were normalized against the absor-
bance values at 405 nm observed for the corresponding non-digested
glycosaminoglycan (GAG), and which were set at 100%. Data are given
as mean with standard deviation in error bars (n = 3 in duplicate)
Fig. 4 Binding of (a) FGF2 and
(b) VEGF (incubated at 25 ng/
well) to immobilized heparin,
heparan sulfate (HS), chondroitin-
6-sulfate (CSC), dermatan sulfate
(DS) (incubated at 500 ng/well)
and to the well without glycos-
aminoglycans (no GAGs). The
bound growth factors were de-
tected via an indirect ELISA
using rabbit anti-fibroblast
growth factor-basic and goat anti-
human VEGF 165 antibody. Data
were normalized against the
maximum absorbance values ob-
tained at 405 nm, which in this
case were the growth factors
bound to heparin. Data are pre-
sented as the relative binding of
the growth factors corrected for
the blank (coating with 80% (v/v)
(NH4)2SO4 without growth fac-
tor). Data are given as mean with
standard deviation in error bars
(n = 3 in duplicate)
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Having identified (NH4)2SO4 as the most efficient salt for
the immobilization of GAGs, the optimum salt saturation per-
centage was assessed. Heparin, CSC and heparan sulfate (HS)
were immobilized using various saturation percentages of
(NH4)2SO4 and of sodium chloride (NaCl) as a less effective
salt. The 100, 90, 80 and 70% (v/v) saturated solutions of
(NH4)2SO4 were more efficient in immobilizing heparin com-
pared to solutions of with lesser degrees of saturation and all
solutions of NaCl (Fig. 2a). For the immobilization of CSC,
solutions of (NH4)2SO4 of 50, 60, 70, 80, 90 and 100% (v/v)
saturation were most efficient, where none of the NaCl solu-
tions showed more than 20% of the maximum binding using
(NH4)2SO4 (Fig. 2b). The overall highest percentage of im-
mobilization for heparin was obtained using 100% (v/v)
(NH4)2SO4, while for CSC and HS (Fig. 2c) this was 80%
(v/v). For further experiment we used an 80% (v/v) saturated
(NH4)2SO4 solution for immobilization of all GAGs.
Enzymatic digestion of immobilized GAGs
To verify whether immobilized GAGs were still bioavailable
for glycolytic enzymes, immobilized heparin and HS were
incubated with a mix of heparinase I, II and III. Immobilized
CSC and dermatan sulfate (DS) were incubated with
Fig. 5 Construction of gradients
of heparin and FGF2 in a 24-wells
plate (diameter of the well ≈
1.6 cm). (a) A block gradient of
heparin created by the stepwise
dilutions of 2 μg heparin with
80% (v/v) saturated (NH4)2SO4
solution (see text for details). (b)
A block gradient of FGF2 created
by incubation of a heparin block
gradient with 80 ng FGF2 in 0.4%
(w/v) BSA in PBS for 1 h. (c) A
continuous gradient of heparin
created by continuously diluting
2 μg heparin with 80% (v/v) sat-
urated (NH4)2SO4 solution using
a pump device at a rate of 0.1 ml/h
(see text for details). Heparin and
FGF2 were
immunohistochemically detected
using HS4C3Vand rabbit anti-
fibroblast growth factor respec-
tively and visualized with IgG
conjugated IRDye 800CWon a
Odyssey CLx imaging system.
Using Fiji 1.51n software a gra-
dient profile was plotted by
drawing a line from high to low
concentrations of heparin. The
gray value (a.u.) was determined
along the distance of this line.
Distances, spanning the gradient,
are indicated in μm’s. a.u. = arbi-
trary units
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chondroitinase ABC for this reason. After digestion, a major
reduction in immobilized GAGs was observed (Fig. 3), indi-
cating good accessibility for enzymatic degradation.
Growth factor binding to immobilized GAGs
To evaluate the capacity of the immobilized GAGs to bind
growth factors, FGF2 and VEGF were allowed to bind to
immobilized heparin, HS, CSC and DS. All immobilized
GAGs were able to bind FGF2 and VEGF, with heparin
resulting in the highest amounts of detected growth factors
(Fig. 4a, b). Furthermore, a higher amount of FGF2 and
VEGF were detected on immobilized DS compared to HS
and CSC.
Creation of a gradient of immobilized heparin
and FGF2
In order to demonstrate the versatility of the immobilization
method, two different types of GAG gradients were created.
Since the immobilization of the GAGs is concentration depen-
dent, we prepared gradients of GAGs on surfaces by a dilution
strategy. A block gradient of heparin was created by pipetting
a concentrated heparin stock solution in 80% (v/v) saturated
(NH4)2SO4 at one side of the well in a 24-wells plate followed
by a stepwise dilution the heparin stock at the same position
with the immobilization solution over time (Fig. 5a). For each
step heparin was diluted with a volume of 100 μl of 80% (v/v)
saturated (NH4)2SO4 followed by 1-h incubation. The hydro-
phobicity of the well and surface tension causes the heparin
solution to maintain its droplet shape during al dilution steps.
This expanding droplet pattern is clearly visible when visual-
izing the obtained block gradient of heparin with immunohis-
tochemical IRDye staining, with each consecutive Bblock^
with decreasing intensity of the IRDye representing one dilu-
tion step. Using the heparin block gradient as a template, a
gradient of FGF2 was obtained by incubation with FGF2 in
the presence of a low amount of BSA to prevent aspecific
binding to the plate (Fig. 5b). The FGF2 gradient followed
the pattern of the heparin block gradient. Finally, a continuous
gradient of heparin was prepared. A heparin stock solution in
80% (v/v) saturated (NH4)2SO4 was pipetted to one side of a
well and continuously diluted with the immobilization solu-
tion from the same starting position using a pump system (Fig.
5c).
Creating patterns of immobilized heparin and CSC
Besides gradients, customized patterns of GAGs can be creat-
ed on surfaces. To illustrate this, a clover-shaped mold was 3D
printed, which tightly fitted in a well of a 24-wells plate (Fig.
6c, d). Heparin in 80% (v/v) saturated (NH4)2SO4 was pipet-
ted inside the mold, while CSC in 80% (v/v) saturated
(NH4)2SO4 was pipetted in another well on the outside of
the mold. In this manner, a clover pattern of heparin and a
reverse clover pattern of CSC were obtained as visualized by
immunohistochemistry (Fig. 6a, b).
Discussion
In this study, we demonstrated the efficient and low-cost im-
mobilization of unmodified GAGs onto plastic surfaces using
highly concentrated salt solutions. We hypothesize that the
applied salt removes the water coat from GAGs and shields
their negatively charges, thereby strongly improving hydro-
phobic interactions of GAGs with surfaces [20]. After wash-
ing away the salt, the GAGs are immobilized to the surface as
demonstrated immunohistochemically using single chain
antibodies.
The efficiency of the GAG immobilization depends on the
nature of the salt. Based on their ability to precipitate or solu-
bilize proteins, salts are considered either cosmotropic or
chaotropic according to the ordering of the Hofmeister series
[27, 28]. It could be hypothesized that the cosmotropic salts of
the Hofmeister series are more efficient in immobilizing
GAGs as they have the best salting-out and protein-
stabilizing characteristics. Indeed, (NH4)2SO4, with both ions
at the cosmotropic end of the Hofmeister series, was the most
efficient salt. Vlachy et al. proposed a Hofmeister-like
Fig. 6 Creation of patterns of immobilized glycosaminoglycans (GAGs)
in a 24-wells plate (diameter of the well ≈ 1.6 cm). (a) Clover-shaped
pattern of heparin. (b) Reverse clover-shaped pattern of chondroitin-6-
sulfate. (c) 3D printed clover-shaped, polylactic acid mold. (d) Mold
placed at the bottom of a 24-wells plate. Patterns were obtained by pipet-
ting the GAGs (8 μg/well) inside or outside the mold and immobilization
with 80% (v/v) saturated (NH4)2SO4 solution. Heparin was
immunohistochemically detected using HS4C3V in combination with
IgG conjugated IRDye 800CW and CSC using IO3H10 in combination
with IgG conjugated with IRDye 680CW followed by visualization on
the Odyssey CLx imaging system
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ordering of anionic headgroups and their interaction with cat-
ions, suggesting that ammonium will form closer ion pairs
with sulfate compared with other cations e.g. sodium [29].
This close ion pair formation will lead to less hydration and
hence increased hydrophobic interactions. This may explain
why (NH4)2SO4 has a higher GAG immobilization efficiency
even compared to salts with a higher molarity at saturation,
such as LiCl, which would mean a larger number of effective
anions and cations to immobilize the GAGs (see
Supplementary Table 1).
After immobilization of the GAGs, they were still able to
bind the growth factors FGF2 and VEGF, which are both
important in wound healing and angiogenesis [30, 31].
Please note that observed differences in growth factor binding
amongst the various GAGs may be caused by differences in
immobilization efficiency for each GAG. Beside growth fac-
tor binding sites, we demonstrated that the cleavage sites of
heparin, HS, CSC and DS were available for digestion by
GAG lyases. Since the immobilized GAGs remain bioavail-
able, the described method is suitable to study the GAG-
protein interactions underlying biological processes.
Gradients of growth factors are crucial in a variety of
biological processes including embryonic development, an-
giogenesis and inflammatory cell migration [32–34]. We
demonstrated that two different types of heparin gradients
and various GAG patterns can be created using our immo-
bilization method. The heparin gradient can be used to
create gradients of growth factors, as shown for FGF2.
Different types of gradients and patterns of GAGs can be
used to study the role of growth factor gradients on cellular
behavior. For example, Wu et al. demonstrated that the
migration rate of vascular smooth muscle cells is dependent
on the density of the FGF2 gradient [35].
In conclusion, we provide a straightforward method for the
immobilization of unmodified GAGs and the formation of
gradients of GAGs and of GAG-binding molecules. The
method may be generally applicable to study the biological
roles of GAGs.
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